Absolute  ||| S:0 E:9 ||| JJ
quantification  ||| S:9 E:24 ||| NN
of  ||| S:24 E:27 ||| IN
human  ||| S:27 E:33 ||| JJ
tear  ||| S:33 E:38 ||| NNS
lactoferrin  ||| S:38 E:50 ||| VBP
using  ||| S:50 E:56 ||| VBG
multiple  ||| S:56 E:65 ||| JJ
reaction  ||| S:65 E:74 ||| NN
monitoring  ||| S:74 E:85 ||| NN
technique  ||| S:85 E:95 ||| NN
with  ||| S:95 E:100 ||| IN
stable-isotopic  ||| S:100 E:116 ||| JJ
labeling  ||| S:116 E:125 ||| VBG
The  ||| S:125 E:129 ||| DT
mass  ||| S:129 E:134 ||| JJ
spectrometry  ||| S:134 E:147 ||| JJ
technique  ||| S:147 E:157 ||| NN
of  ||| S:157 E:160 ||| IN
multiple  ||| S:160 E:169 ||| JJ
reaction  ||| S:169 E:178 ||| NN
monitoring  ||| S:178 E:189 ||| NN
( ||| S:189 E:190 ||| -LRB-
MRM ||| S:190 E:193 ||| NNP
)  ||| S:193 E:195 ||| -RRB-
was  ||| S:195 E:199 ||| VBD
used  ||| S:199 E:204 ||| VBN
to  ||| S:204 E:207 ||| TO
quantify  ||| S:207 E:216 ||| VB
and  ||| S:216 E:220 ||| CC
compare  ||| S:220 E:228 ||| VB
the  ||| S:228 E:232 ||| DT
expression  ||| S:232 E:243 ||| NN
level  ||| S:243 E:249 ||| NN
of  ||| S:249 E:252 ||| IN
lactoferrin  ||| S:252 E:264 ||| NN
in  ||| S:264 E:267 ||| IN
tear  ||| S:267 E:272 ||| JJ
films  ||| S:272 E:278 ||| NNS
among  ||| S:278 E:284 ||| IN
control ||| S:284 E:291 ||| NN
,  ||| S:291 E:293 ||| ,
prostate  ||| S:293 E:302 ||| JJ
cancer  ||| S:302 E:309 ||| NN
( ||| S:309 E:310 ||| -LRB-
CaP ||| S:310 E:313 ||| NNP
) ||| S:313 E:314 ||| -RRB-
,  ||| S:314 E:316 ||| ,
and  ||| S:316 E:320 ||| CC
benign  ||| S:320 E:327 ||| JJ
prostate  ||| S:327 E:336 ||| NN
hyperplasia  ||| S:336 E:348 ||| NNS
( ||| S:348 E:349 ||| -LRB-
BPH ||| S:349 E:352 ||| NNP
)  ||| S:352 E:354 ||| -RRB-
groups ||| S:354 E:360 ||| NNS
.  ||| S:360 E:362 ||| .
Tear  ||| S:362 E:367 ||| JJ
samples  ||| S:367 E:375 ||| NNS
from  ||| S:375 E:380 ||| IN
14  ||| S:380 E:383 ||| CD
men  ||| S:383 E:387 ||| NNS
with  ||| S:387 E:392 ||| IN
CaP ||| S:392 E:395 ||| NNP
,  ||| S:395 E:397 ||| ,
15  ||| S:397 E:400 ||| CD
men  ||| S:400 E:404 ||| NNS
with  ||| S:404 E:409 ||| IN
BPH ||| S:409 E:412 ||| NNP
,  ||| S:412 E:414 ||| ,
and  ||| S:414 E:418 ||| CC
14  ||| S:418 E:421 ||| CD
controls  ||| S:421 E:430 ||| NNS
were  ||| S:430 E:435 ||| VBD
analyzed  ||| S:435 E:444 ||| VBN
in  ||| S:444 E:447 ||| IN
the  ||| S:447 E:451 ||| DT
study ||| S:451 E:456 ||| NN
.  ||| S:456 E:458 ||| .
Collected  ||| S:458 E:468 ||| JJ
tears  ||| S:468 E:474 ||| NNS
( ||| S:474 E:475 ||| -LRB-
2 μl ||| S:475 E:479 ||| NNP
)  ||| S:479 E:481 ||| -RRB-
of  ||| S:481 E:484 ||| IN
each  ||| S:484 E:489 ||| DT
sample  ||| S:489 E:496 ||| NN
were  ||| S:496 E:501 ||| VBD
digested  ||| S:501 E:510 ||| VBN
with  ||| S:510 E:515 ||| IN
trypsin  ||| S:515 E:523 ||| JJ
overnight  ||| S:523 E:533 ||| JJ
at  ||| S:533 E:536 ||| IN
37 °C  ||| S:536 E:542 ||| CD
without  ||| S:542 E:550 ||| IN
any  ||| S:550 E:554 ||| DT
pretreatment ||| S:554 E:566 ||| NN
,  ||| S:566 E:568 ||| ,
and  ||| S:568 E:572 ||| CC
tear  ||| S:572 E:577 ||| JJ
lactoferrin  ||| S:577 E:589 ||| NN
was  ||| S:589 E:593 ||| VBD
quantified  ||| S:593 E:604 ||| VBN
using  ||| S:604 E:610 ||| VBG
a  ||| S:610 E:612 ||| DT
lactoferrin-specific  ||| S:612 E:633 ||| JJ
peptide ||| S:633 E:640 ||| NN
,  ||| S:640 E:642 ||| ,
VPSHAVVAR ||| S:642 E:651 ||| NNP
,  ||| S:651 E:653 ||| ,
both  ||| S:653 E:658 ||| DT
using  ||| S:658 E:664 ||| VBG
natural ||| S:664 E:671 ||| JJ
/ ||| S:671 E:672 ||| CD
light  ||| S:672 E:678 ||| NN
and  ||| S:678 E:682 ||| CC
isotopic-labeled ||| S:682 E:698 ||| JJ
/ ||| S:698 E:699 ||| CD
heavy  ||| S:699 E:705 ||| JJ
peptides  ||| S:705 E:714 ||| NN
with  ||| S:714 E:719 ||| IN
MRM ||| S:719 E:722 ||| NNP
.  ||| S:722 E:724 ||| .
The  ||| S:724 E:728 ||| DT
average  ||| S:728 E:736 ||| JJ
tear  ||| S:736 E:741 ||| JJ
lactoferrin  ||| S:741 E:753 ||| JJ
concentration  ||| S:753 E:767 ||| NN
was  ||| S:767 E:771 ||| VBD
1.01 ± 0.07 μg ||| S:771 E:785 ||| CD
/ ||| S:785 E:786 ||| CD
μl  ||| S:786 E:789 ||| NN
in  ||| S:789 E:792 ||| IN
control  ||| S:792 E:800 ||| NN
samples ||| S:800 E:807 ||| NNS
,  ||| S:807 E:809 ||| ,
0.96 ± 0.07 μg ||| S:809 E:823 ||| CD
/ ||| S:823 E:824 ||| CD
μl  ||| S:824 E:827 ||| NN
in  ||| S:827 E:830 ||| IN
the  ||| S:830 E:834 ||| DT
BPH  ||| S:834 E:838 ||| NNP
group ||| S:838 E:843 ||| NN
,  ||| S:843 E:845 ||| ,
and  ||| S:845 E:849 ||| CC
0.98 ± 0.07 μg ||| S:849 E:863 ||| CD
/ ||| S:863 E:864 ||| CD
μl  ||| S:864 E:867 ||| NN
in  ||| S:867 E:870 ||| IN
the  ||| S:870 E:874 ||| DT
CaP  ||| S:874 E:878 ||| JJ
group ||| S:878 E:883 ||| NN
.  ||| S:883 E:885 ||| .
Our  ||| S:885 E:889 ||| PRP$
study  ||| S:889 E:895 ||| NN
is  ||| S:895 E:898 ||| VBZ
the  ||| S:898 E:902 ||| DT
first  ||| S:902 E:908 ||| JJ
to  ||| S:908 E:911 ||| TO
quantify  ||| S:911 E:920 ||| VB
tear  ||| S:920 E:925 ||| JJ
proteins  ||| S:925 E:934 ||| NNS
using  ||| S:934 E:940 ||| VBG
a  ||| S:940 E:942 ||| DT
total  ||| S:942 E:948 ||| NN
of  ||| S:948 E:951 ||| IN
43  ||| S:951 E:954 ||| CD
individual  ||| S:954 E:965 ||| NN
( ||| S:965 E:966 ||| -LRB-
non-pooled ||| S:966 E:976 ||| NNP
)  ||| S:976 E:978 ||| -RRB-
tear  ||| S:978 E:983 ||| JJ
samples  ||| S:983 E:991 ||| NNS
and  ||| S:991 E:995 ||| CC
showed  ||| S:995 E:1002 ||| VBD
that  ||| S:1002 E:1007 ||| DT
direct  ||| S:1007 E:1014 ||| JJ
digestion  ||| S:1014 E:1024 ||| NN
of  ||| S:1024 E:1027 ||| IN
tear  ||| S:1027 E:1032 ||| JJ
samples  ||| S:1032 E:1040 ||| NNS
is  ||| S:1040 E:1043 ||| VBZ
suitable  ||| S:1043 E:1052 ||| VBN
for  ||| S:1052 E:1056 ||| IN
MRM  ||| S:1056 E:1060 ||| NNP
studies ||| S:1060 E:1067 ||| NNS
.  ||| S:1067 E:1069 ||| .
The  ||| S:1069 E:1073 ||| DT
calculated  ||| S:1073 E:1084 ||| JJ
average  ||| S:1084 E:1092 ||| JJ
lactoferrin  ||| S:1092 E:1104 ||| JJ
concentration  ||| S:1104 E:1118 ||| NN
in  ||| S:1118 E:1121 ||| IN
the  ||| S:1121 E:1125 ||| DT
control  ||| S:1125 E:1133 ||| NN
group  ||| S:1133 E:1139 ||| NN
matched  ||| S:1139 E:1147 ||| VBN
that  ||| S:1147 E:1152 ||| IN
in  ||| S:1152 E:1155 ||| IN
the  ||| S:1155 E:1159 ||| DT
published  ||| S:1159 E:1169 ||| JJ
range  ||| S:1169 E:1175 ||| NN
of  ||| S:1175 E:1178 ||| IN
human  ||| S:1178 E:1184 ||| JJ
tear  ||| S:1184 E:1189 ||| JJ
lactoferrin  ||| S:1189 E:1201 ||| JJ
concentration  ||| S:1201 E:1215 ||| NN
measured  ||| S:1215 E:1224 ||| VBN
by  ||| S:1224 E:1227 ||| IN
enzyme-linked  ||| S:1227 E:1241 ||| JJ
immunosorbent  ||| S:1241 E:1255 ||| JJ
assay  ||| S:1255 E:1261 ||| NNS
( ||| S:1261 E:1262 ||| -LRB-
ELISA ||| S:1262 E:1267 ||| NNP
) ||| S:1267 E:1268 ||| -RRB-
.  ||| S:1268 E:1270 ||| .
Moreover ||| S:1270 E:1278 ||| RB
,  ||| S:1278 E:1280 ||| ,
the  ||| S:1280 E:1284 ||| DT
lactoferrin  ||| S:1284 E:1296 ||| NN
was  ||| S:1296 E:1300 ||| VBD
stably  ||| S:1300 E:1307 ||| VBN
expressed  ||| S:1307 E:1317 ||| VBN
across  ||| S:1317 E:1324 ||| IN
all  ||| S:1324 E:1328 ||| DT
of  ||| S:1328 E:1331 ||| IN
the  ||| S:1331 E:1335 ||| DT
samples ||| S:1335 E:1342 ||| NNS
,  ||| S:1342 E:1344 ||| ,
with  ||| S:1344 E:1349 ||| IN
no  ||| S:1349 E:1352 ||| DT
significant  ||| S:1352 E:1364 ||| JJ
differences  ||| S:1364 E:1376 ||| NNS
being  ||| S:1376 E:1382 ||| VBG
observed  ||| S:1382 E:1391 ||| VBN
among  ||| S:1391 E:1397 ||| IN
the  ||| S:1397 E:1401 ||| DT
control ||| S:1401 E:1408 ||| NN
,  ||| S:1408 E:1410 ||| ,
BPH ||| S:1410 E:1413 ||| NNP
,  ||| S:1413 E:1415 ||| ,
and  ||| S:1415 E:1419 ||| CC
CaP  ||| S:1419 E:1423 ||| JJ
groups ||| S:1423 E:1429 ||| NNS
.  ||| S:1429 E:1431 ||| .
